Io Therapeutics, Inc. Specializing in immuno-oncology, autoimmune therapeutics, and neurotherapeutics, their mission is to discover and develop revolutionary therapeutic compounds that target nuclear receptors for the treatment of cancer, neurodegenerative diseases, and autoimmune conditions. Their innovative approach focuses on the use of retinoids and rexinoids, which are small molecule drugs derived from retinoic acid.

These drugs interact with nuclear receptors to control the expression of various genes. Io Therapeutics is particularly interested in retinoic acid receptors (RARs) and retinoic acid X receptors (RXRs), which have three subtypes each. The discovery of these nuclear receptor families has brought about significant breakthroughs in cancer biology, the understanding of degenerative diseases like Alzheimer's and Parkinson's, and the immune system's dysregulation in autoimmune disorders.

With a dedicated team of experts, Io Therapeutics is at the forefront of groundbreaking research and development, aiming to improve the lives of patients worldwide